We therefore investigated whether the rapid reactivation of MAPK signalling in FGFR-fusion harbouring bladder cancer cells could be attenuated by combined treatment with an FGFR inhibitor and the pan-ERBB inhibitor, AZD8931, and whether this could enhance the growth inhibitory effect of FGFR inhibitors. This evidence concerns the gene EGFR and urinary bladder carcinoma.